Table 1 Serum and Tissue measurements.

From: Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice

 

control

HFD

FEN-HFD

Serum levels

 Basal Glucose Week 11 (mmol/L)

9.32 ± 0.57

9.51 ± 0.76

11.12 ± 0.51

 Basal Glucose Week 12 (mmol/L)

7.65 ± 0.65

8.67 ± 0.57

9.75 ± 0.56

 Insulin (ng/ml)

1.23 ± 0.37

0.82 ± 0.12

0.69 ± 0.07

 Leptin (ng/ml)

6.94 ± 3.03

15.79 ± 3.75

7.56 ± 1.43

 Cholesterol (µg)

5.96 ± 1.00

17.21 ± 1.60 ****

17.19 ± 0.57 ****

 Triglyceride (mg/ml)

1.76 ± 0.195

4.41 ± 0.43 ***

7.95 ± 0.60 ****/####

Tissue levels

 Liver triglyceride (µg/mg)

14.24 ± 1.47

35.28 ± 6.34 **

13.82 ± 0.97##

  1. Data are represented as mean ± S.E.M. (n = 8 per group) and analysed by One-way ANOVA followed by Bonferroni multiple comparison t-tests where **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 (control compared to HFD) or ## p ≤ 0.01 and #### p ≤ 0.0001 (HFD compared to FEN-HFD).
Back to article page